Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05726032 · ClinicalTrials.gov registry record · Phase 2
Empagliflozin in Patients With Cirrhosis and Ascites
A Phase 2 study of Cirrhosis and Liver Failure, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05726032: Recruiting Phase 2 study of Cirrhosis and Liver Failure, sponsored by Yale University.
NCT05726032 is a Phase 2 study of Cirrhosis and Liver Failure that is actively recruiting participants, run by Yale University. The registered enrollment target is 20 participants, below the 90,409-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05726032, a Phase 2 study of Cirrhosis and Liver Failure, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
A proof-of-concept placebo-controlled trial to explore the acute and 14-day effects of empagliflozin on natriuresis and total body water in patients with cirrhosis and ascites. We will additionally investigate its effect on neurohumoral activation, and renal hemodynamics.
Primary Outcome
Change in fractional excretion of sodium with administration of study drug (10 mg empagliflozin vs. identical placebo)
Conditions Studied
Interventions
- DRUG Empagliflozin 10 MG
- DRUG Matching Placebo
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-09-11 |
| Est. Completion | 2026-06-01 |
| Phase | Phase 2 |
What NCT05726032 shows while recruiting
NCT05726032 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 90,409-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Cirrhosis appearing as the primary indexed condition, and to 2 interventions - of which Empagliflozin 10 MG is the first listed.
NCT05726032 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05726032 about?
NCT05726032 is a clinical study titled "Empagliflozin in Patients With Cirrhosis and Ascites". A proof-of-concept placebo-controlled trial to explore the acute and 14-day effects of empagliflozin on natriuresis and total body water in patients with cirrhosis and ascites. We will additionally investigate its effect on neurohumoral activation, and renal hemodynamics.
What is the current status of trial NCT05726032?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2023-09-11. Estimated completion is 2026-06-01.
What conditions does trial NCT05726032 study?
This clinical trial studies the following conditions: Cirrhosis, Liver Failure.
What interventions are being tested in trial NCT05726032?
The interventions under investigation include: Empagliflozin 10 MG (DRUG), Matching Placebo (DRUG).
Who is sponsoring clinical trial NCT05726032?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05726032 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05726032's enrollment target sits among peer trials
20 44th of 53 higher than 8 of 53 other Cirrhosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cirrhosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
RECRUITING · Phase 2
-
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
RECRUITING · Phase 2
-
Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis
RECRUITING · Phase 2
-
Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI